{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T14:46:27Z","timestamp":1776523587524,"version":"3.51.2"},"reference-count":24,"publisher":"Japanese Society of Internal Medicine","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,2,1]]},"DOI":"10.2169\/internalmedicine.5838-25","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T18:08:48Z","timestamp":1751479728000},"page":"464-468","source":"Crossref","is-referenced-by-count":3,"title":["Combined Alport Syndrome Type 3A and Mitochondrial Disease Presenting with a Thin Base Membrane and Overt Albuminuria"],"prefix":"10.2169","volume":"65","author":[{"given":"Daisuke","family":"Nakashima","sequence":"first","affiliation":[{"name":"Department of Nephrology, Kawaguchi Municipal Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Tosaki","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Kawaguchi Municipal Medical Center, Japan"},{"name":"Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaya","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Kawaguchi Municipal Medical Center, Japan"},{"name":"Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Honda","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Kawaguchi Municipal Medical Center, Japan"},{"name":"Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Yokote","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Kawaguchi Municipal Medical Center, Japan"},{"name":"Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayasu","family":"Mori","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Institute of Science Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eisei","family":"Sohara","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Institute of Science Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Uchida","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Institute of Science Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuo","family":"Tsuboi","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Yokoo","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Kashtan CE, Michael AF. Alport syndrome. Kidney Int 50: 1445-1463, 1996.","DOI":"10.1038\/ki.1996.459"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Kashtan CE, Ding J, Garosi G, et al. Alport syndrome: a unified classification of genetic disorders of collagen IV \u03b1345: a position paper of the Alport Syndrome Classification Working Group. Kidney Int 93: 1045-1051, 2018.","DOI":"10.1016\/j.kint.2017.12.018"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Gorman GS, Chinnery PF, DiMauro S, et al. Mitochondrial diseases. Nat Rev Dis Primers 2: 16080, 2016.","DOI":"10.1038\/nrdp.2016.80"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4. Goto Y, Nonaka I, Horai S. A mutation in the tRNA<sup>Leu (UUR)<\/sup> gene associated with the MELAS subgroup of mitochondrial encephalomyopathies. Nature 348: 651-653, 1990.","DOI":"10.1038\/348651a0"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Mori T, Hosomichi K, Chiga M, et al. Comprehensive genetic testing approach for major inherited kidney diseases, using next-generation sequencing with a custom panel. Clin Exp Nephrol 21: 63-75, 2017.","DOI":"10.1007\/s10157-016-1252-1"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. DiMauro S, Schon EA. Mitochondrial respiratory-chain diseases. N Engl J Med 348: 2656-2668, 2003.","DOI":"10.1056\/NEJMra022567"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Fang F, Liu Z, Fang H, et al. The clinical and genetic characteristics in children with mitochondrial disease in China. Sci China Life Sci 60: 746-757, 2017.","DOI":"10.1007\/s11427-017-9080-y"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Imasawa T, Rossignol R. Podocyte energy metabolism and glomerular diseases. Int J Biochem Cell Biol 45: 2109-2118, 2013.","DOI":"10.1016\/j.biocel.2013.06.013"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Imasawa T, Hirano D, Nozu K, et al.; J-SMiN Collaborators. Clinicopathologic features of mitochondrial nephropathy. Kidney Int Rep 7: 580-590, 2022.","DOI":"10.1016\/j.ekir.2021.12.028"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Hall AM, Vilasi A, Garcia-Perez I, et al. The urinary proteome and metabonome differ from normal in adults with mitochondrial disease. Kidney Int 87: 610-620, 2015.","DOI":"10.1038\/ki.2014.297"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Imasawa T, Murayama K, Hirano D, Nozu K. Comprehensive review of mitochondrial nephropathy - a renal phenotype in mitochondrial disease: causative genes, clinical and pathological features, diagnosis, prognosis, and treatment. Clin Exp Nephrol 29: 39-56, 2025.","DOI":"10.1007\/s10157-024-02554-y"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Stewart JB, Chinnery PF. The dynamics of mitochondrial DNA heteroplasmy: implications for human health and disease. Nat Rev Genet 16: 530-542, 2015.","DOI":"10.1038\/nrg3966"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Furlano M, Mart\u00ednez V, Pybus M, et al. Clinical and genetic features of autosomal dominant Alport syndrome: a cohort study. Am J Kidney Dis 78: 560-570, 2021.","DOI":"10.1053\/j.ajkd.2021.02.326"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Kamiyoshi N, Nozu K, Fu XJ, et al. Genetic, clinical, and pathologic backgrounds of patients with autosomal dominant Alport syndrome. Clin J Am Soc Nephrol 11: 1441-1449, 2016.","DOI":"10.2215\/CJN.01000116"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Savige J, Ariani F, Mari F, et al. Expert consensus guidelines for the genetic diagnosis of Alport syndrome. Pediatr Nephrol 34: 1175-1189, 2019.","DOI":"10.1007\/s00467-018-3985-4"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Richards S, Aziz N, Bale S, et al.; the ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17: 405-424, 2015.","DOI":"10.1038\/gim.2015.30"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Yasukawa T, Suzuki T, Ueda T, Ohta S, Watanabe K. Modification defect at anticodon wobble nucleotide of mitochondrial tRNAs<sup>Leu<\/sup> (UUR) with pathogenic mutations of mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes. J Biol Chem 275: 4251-4257, 2000.","DOI":"10.1074\/jbc.275.6.4251"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Ohsawa Y, Hagiwara H, Nishimatsu SI, et al.; the KN01 Study Group. Taurine supplementation for prevention of stroke-like episodes in MELAS: a multicentre, open-label, 52-week phase III trial. J Neurol Neurosurg Psychiatry 90: 529-536, 2019.","DOI":"10.1136\/jnnp-2018-317964"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Imasawa T, Kitamura H, Kawaguchi T, Yatsuka Y, Okazaki Y, Murayama K. Changes in histopathology and heteroplasmy rates over 8 years and effectiveness of taurine supplementation in a patient with mitochondrial nephropathy caused by <i>MT-TL1<\/i> mutation: a case report. Heliyon 9: e14923, 2023.","DOI":"10.1016\/j.heliyon.2023.e14923"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Zhu Z, Rosenkranz KAT, Kusunoki Y, et al. Finerenone added to RAS\/SGLT2 blockade for CKD in Alport syndrome. Results of a randomized controlled trial with <i>Col4a3<sup>-\/-<\/sup><\/i> mice. J Am Soc Nephrol 34: 1513-1520, 2023.","DOI":"10.1681\/ASN.0000000000000186"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Koga Y, Povalko N, Inoue E, et al. Therapeutic regimen of l-arginine for MELAS: 9-year, prospective, multicenter, clinical research. J Neurol 265: 2861-2874, 2018.","DOI":"10.1007\/s00415-018-9057-7"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Ibayashi K, Fujino Y, Mimaki M, Fujimoto K, Matsuda S, Goto YI. Estimation of the number of patients with mitochondrial diseases: a descriptive study using a nationwide database in Japan. J Epidemiol 33: 68-75, 2023.","DOI":"10.2188\/jea.JE20200577"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Gibson J, Fieldhouse R, Chan MMY, et al.; the Genomics England Research Consortium. Prevalence estimates of predicted pathogenic <i>COL4A3-COL4A5<\/i> variants in a population sequencing database and their implications for Alport syndrome. J Am Soc Nephrol 32: 2273-2290, 2021.","DOI":"10.1681\/ASN.2020071065"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Sumida K, Nadkarni GN, Grams ME, et al.; the Chronic Kidney Disease Prognostic Consortium. Conversion of urine protein-creatinine ratio or urine dipstick protein to urine albumin-creatinine ratio for use in chronic kidney disease screening and prognosis: an individual participant-based meta-analysis. Ann Intern Med 173: 426-435, 2020.","DOI":"10.7326\/M20-0529"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/3\/65_5838-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T03:47:01Z","timestamp":1770436021000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/3\/65_5838-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,1]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.5838-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,1]]},"article-number":"5838-25"}}